Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Eris Lifesciences Limited, together with its subsidiaries, provides domestic branded formulations for chronic and sub-chronic therapies in India. The company offers various branded formulations in various therapeutic areas, such as anti–diabetes, cardiovascular, nutrition, dermatology, neuroscience, gynecology, nephrology, and oncology, as well as central nervous system, women's health, and vitamins/minerals/nutrients. It also provides patient care services, including ambulatory blood pressure measurement, ambulatory electrocardiogram measurement, continuous glucose monitoring system, sleep study, and ante-natal care solutions. It offers its products through wholesale drug distributors, and stockiest and retail pharmacies. Eris Lifesciences Limited was incorporated in 2007 and is based in Ahmedabad, India.

Revenue projections:

Revenue projections for ERIS
Revenue projections for ERIS

Investors are expected to be cautious with ERIS, as its revenues are projected to fall compared to last year. A decline in revenue often results in a negative impact on profitability, prompting concerns about the company's financial stability and making investors more conservative in their approach.

Financial Ratios:

currentRatio 0.914000
forwardPE 26.346287
debtToEquity 68.185000
earningsGrowth 0.311000
revenueGrowth 0.069000
grossMargins 0.747730
operatingMargins 0.277330
trailingEps 30.480000
forwardEps 52.591850

ERIS's Forward PE is in a strong range, indicating that its stock price compares well with its earnings. The stock is not considered overpriced, leaving ample room for growth and making it a promising option for investors looking for value and future returns.
ERIS's positive gross and operating margins suggest that the company is operating profitably. These strong margins indicate effective cost management and revenue generation, contributing to a solid financial foundation.
ERIS's forward EPS exceeding its trailing EPS means that the company is expected to increase profitability in the current financial year. This reflects improved earnings potential, signaling that ERIS is likely to outperform its previous year's financial performance.

Price projections:

Price projections for ERIS
Price projections for ERIS

The present price of ERIS in relation to its projections indicates a lack of clear risks or opportunities. This balanced situation suggests that investors may find it prudent to wait for further signals before making significant moves in the stock.

Recommendation changes over time:

Recommendations trend for ERIS
Recommendations trend for ERIS


A recent buy bias from analysts toward ERIS indicates strong confidence in the stock's future performance. This could encourage investors to park their money in ERIS, viewing it as a stable and potentially rewarding investment opportunity with promising long-term growth prospects.